Stockscreener 앱 받기
26.34
0.53%
0.14
시간 외 거래:
26.20
-0.14
-0.53%
전일 마감가:
$26.20
열려 있는:
$26.51
하루 거래량:
1.92M
Relative Volume:
0.40
시가총액:
$19.56B
수익:
$956.00K
순이익/손실:
$-221.32M
주가수익비율:
-82.31
EPS:
-0.32
순현금흐름:
$-142.25M
1주 성능:
+3.70%
1개월 성능:
+28.11%
6개월 성능:
+19.19%
1년 성능:
+199.83%
1일 변동 폭
$26.23
$27.25
1주일 범위
$24.09
$28.62
52주 변동 폭
$8.80
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
26.34 | 18.86B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Is Summit Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Summit Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
What drives Summit Therapeutics Inc. stock priceFree Investment Community - jammulinksnews.com
What analysts say about Summit Therapeutics Inc. stockHigh-return market picks - Autocar Professional
Published on: 2025-07-19 02:49:19 - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire
Principal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
10 Stocks Exploding Higher: Bitcoin Miners Dominate the List - Insider Monkey
how summit therapeutics inc. stock performs during market volatilityAnalyst Grade Signals - Newser
Summit Therapeutics Jumps 16% On Heavy Volume As Technicals Signal Bullish Breakout - AInvest
Summit Therapeutics Inc (SMMT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Summit Therapeutics Explodes 12%: Legal Probe Ignites Volatility Amid Regulatory Crosshairs - AInvest
Summit Therapeutics Soars 16.5% Amid Regulatory Crossroads and Whale Activity - AInvest
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What makes Summit Therapeutics Inc. stock price move sharplyFree Predictions - Newser
H.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Why Summit Therapeutics Inc. stock attracts strong analyst attentionFree Trading Group - Newser
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - FinancialContent
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - WV News
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
Where are the Opportunities in (SMMT) - news.stocktradersdaily.com
10 Stocks Going Wild - Insider Monkey
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal - Insider Monkey
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca - Yahoo Finance
Pomerantz LLP Investigates Claims Against Summit Therapeutics Inc. - AInvest
Summit Therapeutics: A $15B Oncology Gamble with Ivonescimab - AInvest
Summit Therapeutics' $15 Billion Gamble: Balancing Hope and Hurdles in Lung Cancer Therapeutics - AInvest
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report - NewsBreak: Local News & Alerts
AstraZeneca and Summit Therapeutics: A $15 Billion Gamble on Lung Cancer's Next Breakthrough? - AInvest
Why Summit Therapeutics Stock Soared 8% Higher Today - Nasdaq
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment - Benzinga
AstraZeneca Discusses $15 Billion Partnership With Summit Therapeutics, Bloomberg Says, Citing Sources - MarketScreener
Summit Therapeutics’ Stock Surges Amid AstraZeneca Talks - TipRanks
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
0.87%
자본화:
|
볼륨(24시간):